The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell ...
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve ...
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder ...
Sarepta Therapeutics has put in place several initiatives to help its gene therapy Elevidys return to growth, but recovery ...
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past ...
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, ...
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...
While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on ...
The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...
Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...
Robert F. Kennedy Jr.’s health department has consistently touted radical transparency as being key to its mission. Recent ...
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results